Research ArticleExperimental Studies

Protective Effects of Crocetin on Arsenic Trioxide-induced Oxidative Stress in Human Umbilical Vein Endothelial Cells

CHUNG-LIN TSAI, CHIA-WEN TSAI, WEN-SHIN CHANG, JIUNN-CHERNG LIN, LIANG-CHUN SHIH, JIE-LONG HE and DA-TIAN BAU
In Vivo November 2021, 35 (6) 3157-3163; DOI: https://doi.org/10.21873/invivo.12610

Abstract

Background/Aim: The clinical use of arsenic trioxide (As2O3) is hampered due to its cardiotoxicity. Therefore, it is critical to prevent As2O3-induced loss of endothelial integrity. The purpose of this study was to examine As2O3-induced endothelial dysfunction and evaluate the efficacy of crocetin on reversing As2O3-induced cardiotoxicity. Materials and Methods: Cultured human umbilical vein endothelial cells (HUVECs) were used to examine As2O3-induced oxidative stress, apoptosis, production of reactive oxygen species (ROS) and DNA adducts. In addition, the impact of crocetin on As2O3-induced cardiotoxicity was evaluated. Results: As2O3 decreased the viability of HUVEC cells and led to apoptosis. Additionally, As2O3 elevated NADPH oxidase activity, and the levels of intracellular ROS. Furthermore, the formamidopyrimidine DNA-glycosylase- and endonuclease III-digestible adducts were induced by As2O3. Crocetin treatment reversed the As2O3-induced reduction in cell viability, the induction of apoptosis, the activation of NADPH oxidase activity, ROS levels and DNA adducts. Conclusion: Crocetin protects from As2O3-induced cardio-toxicity.

Arsenic trioxide (As2O3) is a very toxic agent used in Chinese medicine, which has been used to successfully treat refractory acute promyelocytic leukemia (1). The efficacy of As2O3 has been reported for its capacity to induce acute promyelocytic leukemia cells to undergo apoptosis, however, its cardio-toxicity has hindered its therapeutic application (2, 3). In addition, accumulated literature has pointed that chronic exposure to As2O3 from drinking water is closely associated with various human diseases, including atherosclerosis (4), diabetes mellitus (5), hypertension (6), ischemic heart disease (7, 8), peripheral vascular disease (9), and cancer (10, 11). Up to date, relatively few published articles are available on the influence of acute or chronic As2O3 exposure on the vascular endothelial system. At the same time, the identification of potential traditional Chinese medicine for the prevention of the diseases associated with chronic exposure to As2O3 is of great interest. Εndothelial cells, human umbilical vein endothelial cells (HUVEC) are frequently used as the cell model, are the main targets of vasculopathy caused by As2O3 exposure. As2O3 has been reported to cause oxidative stress, and induce endothelial cells to undergo programmed cell death (12). Oxidative stress and its intracellular consequences are believed to be the major cause of As2O3 cytotoxicity (13).

Crocetin (C20H24O4; molecular weight 328.4g/mol) is a primary constituent of saffron (Crocus sativus L), which has been known to possess lots of beneficial pharmacological effects, such as anti-inflammatory (14) and anti-apoptotic (15, 16). Crocetin has also been reported to effectively eliminate ischemia-reperfusion-induced oxidative damage in rats and scavenge free radicals (17). More interesting, crocetin has beneficial cardiovascular effects, such as reducing oxidative stress (18), atherosclerosis (19), hypertension (20) and cardiac hypertrophy (21, 22). Crocetin has also been reported to significantly enhance glutathione peroxidase and superoxide dismutase activities (18). In addition, crocetin can regulate various myocardial enzymes, and collaborate with them to reduce cardio-toxicity and apoptosis (18, 23). However, the effect of crocetin on the DNA level has never been studied.

Based on the aforementioned findings, the current study aimed to evaluate the effects of As2O3 exposure on HUVEC cells in relation to apoptosis, oxidative stress, and DNA adducts, and to investigate whether and how crocetin reverses As2O3 toxicity.

Materials and Methods

Cell line and chemicals. Human umbilical vein endothelial cells (HUVECs) (American Type Culture Collection, CRL-1730, Manassas, VA, USA) were cultured in RPMI-1640 (Hyclone, UT, USA) containing 10% fetal calf serum. As2O3, crocetin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), and dimethyl sulfoxide (DMSO) were obtained from Sigma Chemical Company (St. Louis, MO, USA).

Cell viability assay. Cell viability of HUVEC cells was tested by MTT assay as previously published (24, 25). After drug treatments, the cells were treated with MTT, and the plates were incubated in the dark for 4 h at 37°C. The intensity was measured with a Multiskan MS ELISA reader (Labsystems, Helsinki, Finland). Each experiment was repeated at least thrice.

Measurement of cell apoptosis. Cell apoptosis of HUVEC cells was examined as previously published (26, 27). After drug treatments, HUVEC cells were ethanol-fixed and incubated with propidium iodide buffer for 30 min in the dark at 37°C. After the fixing and staining processes, HUVEC cells were filtered through a 40-μm nylon filter and the percentage of HUVEC cells in the sub-G1 phase was analysed by flow cytometry using a FACS Calibur instrument (BD Biosciences, San Jose, CA, USA). Each experiment was repeated at least thrice.

Intracellular ROS production. Intracellular ROS production was measured as previously described (26, 27). After drug treatments, HUVEC cells were harvested, re-suspended in 10 μM DCFH-DA, incubated at 37°C for 30 min, and analyzed by flow cytometry (BD Biosciences). Results are expressed as fold of the untreated control and each experiment was repeated at least thrice.

NADPH oxidase activity. The NADPH oxidase activity of HUVEC cells was checked as previously described (28). After drug treatments, HUVEC cells were harvested and centrifuged for 10 min at 4°C at 10,000 rpm. Then, the pellet was re-suspended to measure the activity of NADPH oxidase. The reaction buffer was composed of 100 mM of Tris-HCl, 1 mM of EDTA and 0.2 mM of NADPH. The NADPH oxidase activity correlated with the decrease in absorbance at 340 nm. Each experiment was repeated at least thrice.

Comet assay for oxidative DNA adducts. The FPG- and endonuclease III-digestible adducts of HUVEC cells were examined as previously described (28). Briefly, after preparation of typical 3-layer agarose gel slides, the slides were lysed, washed, and incubated at 37°C for 30 min. Then, formamidopyrimidine DNA-glycosylase (FPG) or endonuclease III (Trevigen, Gaithersburg, MD, USA) together with the enzyme reaction buffer were added and further incubated at 37°C for 2 h. Then, the slides were put at 4°C for 18 h, followed by incubation in an alkaline solution for 20 min, and then electrophoresed and stained by SYBR green I. The comet moment was quantified with the formula ∑0→n [(amount of DNA at distance X)×(distance X)]/total DNA. For each sample, at least 50 cells were detected.

Statistical methodology. Results are shown as the mean±SEM for each repeated data. Statistical significance was assessed by the Student’s t-test or one-way ANOVA with post hoc test using the SPSS (version 15.0) software (SPSS Inc., Chicago, IL, USA). p-Values<0.05 were considered statistically significant.

Results

As2O3-induced cytotoxicity was reversed by crocetin. The ability of As2O3 to induces cytotoxicity in HUVEC cells was analyzed. Treatment with 0, 4, 8, 16, and 32 μM of As2O3induced a dose-dependent decrease in cell viability as visualized by microscopy (Figure 1A). In detail, cell viability of HUVEC cells treated with 4 μM As2O3 was not significantly affected (Figure 1B). However, treatment with 8, 16, and 32 μM of As2O3 for 24 h, led to 83.6, 58.4, and 21.5% cell viability, respectively (Figure 1B). Treatment with crocetin reversed the 16 and 32 μM As2O3-induced suppression in cell viability (Figure 1C).

Figure 1.
Figure 1.

The effects of As2O3 and crocetin on HUVEC cell viability. (A) HUVEC cells are observed under a microscope at 40X after 24-h treatment with 0, 4, 8, 16, and 32 μM As2O3. (B) The quantitation results of 0~32 μM As2O3 treatment for 24 h in HUVEC cells. Data are presented as mean±SD of at least three experiments. *Statistically significant (p<0.05) compared with the untreated group. (C) Treatments of various doses of crocetin with 32 μM (◆), 16 μM (▲), or 0 μM (●) As2O3 for 24 h. Data are presented as mean±SD of at least three experiments. *Statistically significant (p<0.05) compared with the control (As2O3 alone) group.

As2O3-induced apoptosis was reversed by crocetin. The ability of As2O3 to induce cell apoptosis in HUVEC cells was then analyzed. Treatment of HUVEC cells with As2O3 concentrations higher than 8 μM for 24 h led to apoptosis (Figure 2A). At 8, 16, and 32 μM, As2O3 induced 21.7, 38.3, and 66.1% of HUVEC cells to undergo apoptosis, respectively (Figure 2A). Treatments with crocetin reversed the 16 and 32 μM As2O3-induced cell apoptosis (Figure 2B).

Figure 2.
Figure 2.

The effects of As2O3 and crocetin on HUVEC cell apoptosis. (A) The effects of 24-h treatment of 0~32 μM As2O3 on HUVEC cells. Apoptotic cells were detected by flow cytometry with sub-G1. Data were present as mean±SD for at least 3 experiments. *Statistically significant (p<0.05) compared with untreated group. (B) Treatments of various doses of crocetin with 32 μM (◆), 16 μM (▲) or 0 μM (●) As2O3 for 24 h. Data were present as mean±SD for at least 3 experiments. *Statistically significant (p<0.05) compared with the control (As2O3 alone) group.

As2O3-induced oxidative stress was suppressed by crocetin. As2O3 treatment induced the production of ROS dose-dependently at the range of 4~16 μM at 24 h (Figure 3). The 4, 8, and 16 μM As2O3-induced ROS could be suppressed by treatment with 10 and 20 μM of crocetin, respectively (Figure 3).

Figure 3.
Figure 3.

The effects of As2O3 and crocetin on ROS production in HUVEC cells. Treatments of 4, 8, or 16 μM As2O3 with or without 10 or 20 μM crocetin for 12 h. Data are presented as mean±SD of at least three experiments. *Statistically significant (p<0.05) compared with the control (As2O3 alone) group.

As2O3-activated NADPH oxidase was suppressed by crocetin. Four, 8, 16, and 32 μM As2O3 treatment activated NADPH oxidase activity by 2.4-, 3.0-, 3.3- and 4.6-fold, respectively (Figure 4A). Treatment with crocetin suppressed the As2O3-activated NADPH oxidase activity in a dose-dependent manner (Figure 4B).

Figure 4.
Figure 4.

The effects of As2O3 and crocetin on NADPH oxidase activity in HUVEC cells. (A) The effects of treatment of 0~32 μM As2O3 on NADPH oxidase activity in HUVEC cells. Data are presented as mean±SD for at least three experiments. *Statistically significant (p<0.05) compared with the untreated group. (B) Treatment of various doses of crocetin with 32 μM (◆), 16 μM (▲), or 0 μM (●) As2O3 for 24 h. Data are presented as mean±SD of at least three experiments. *Statistically significant (p<0.05) compared with the control (As2O3 alone) group.

As2O3-induced FPG- and Endonuclease III-digestible DNA adducts was suppressed by crocetin. As2O3 treatment induced FPG- and endonuclease III-digestible adducts dose-dependently at 4, 8, and 16 μM (Figure 5 and Figure 6). The oxidative adducts were effectively reduced by treatment with 10 and 20 μM of crocetin, and the reducing efficacy was higher at 20 μM (Figure 5 and Figure 6).

Figure 5.
Figure 5.

The effects of As2O3 and crocetin on FPG-digestible adducts in HUVEC cells. Treatments of 4, 8, or 16 μM As2O3 with or without 10 or 20 μM crocetin for 12 h. Data are presented as mean±SD of at least three experiments. & and *statistically significant (p<0.05) compared with the untreated and control (As2O3 alone) groups, respectively.

Figure 6.
Figure 6.

The effects of As2O3 and crocetin on Endonuclease III-digestible adducts in HUVEC cells. Treatments of 4, 8 or 16 μM As2O3 with or without 10 or 20 μM crocetin for 12 h. Data are presented as mean±SD of at least three experiments. & and *statistically significant (p<0.05) compared with the untreated and control (As2O3 alone) groups, respectively.

Discussion

Increased apoptosis of HUVEC cells may be closely related to loss of endothelial integrity, leading to vascular disorders (29, 30). Our results confirmed that As2O3 can induce HUVEC cells to undergo apoptosis, while crocetin can effectively rescue the As2O3-induced HUVEC programmed cell death (Figure 2B). In this study, As2O3-induced apoptosis was not as severe as that in Yu’s experiments, where 5 μM As2O3 induced about 40% apoptosis (31). Our results are consistent with those of Ma’s findings, which showed that 5 μM As2O3 was able to induce about 20% apoptosis in HUVEC cells (32). The differences may be probably due to different culturing passages of HUVEC cells. Treatment with crocetin was found to effectively reverse the As2O3-induced apoptosis in HUVEC cells (Figure 2B). The As2O3-induced ROS production started to increase at 30 min, and could be sustained for 12 h (data not shown). Here, we only show the ROS status at 12 h (Figure 3). Treatment with crocetin did not alter the levels of ROS (Figure 3), but suppressed the As2O3-induced induction of ROS levels, and 20 μM was more effective than 10 μM of crocetin (Figure 3). In a rat model, crocetin has been reported to not only induce the activities of superoxide dismutase, glutathione-peroxidase, and catalase, but also decrease the levels of malondialdehyde and ROS (33).

A number of cardiovascular disorders, such as atherosclerosis and hypertension, have been closely related to increased vascular ROS levels, which has been designated as oxidative stress (34, 35). Our studies showed that As2O3 activated NADPH oxidase, and that treatment with crocetin can effectively reverse it (Figure 4B). This may be the major mechanism related to As2O3-mediated intracellular ROS generation. There is no doubt that As2O3-induced ROS production could be due to different mechanisms other than NADPH oxidase, and could cause different consequences. For instance, As2O3 has been reported to induce the loss of mitochondrial membrane potential and ROS formation, leading to DNA damage and cell apoptosis (36, 37). Moreover, ROS formation has been found to associate with autophagy and other programmed cell death mechanisms (37, 38).

One of the novel findings of this study is the measurement of crocetin-induced suppression of As2O3-induced FPG-digestible adducts and endonuclease III-digestible adducts. The subtle alterations in DNA adducts are one of the end points for understanding how ROS induced intracellular damage and cell death. Consistent with previous findings (28), treatment of As2O3 was capable of inducing FPG-digestible endonuclease III-digestible DNA adducts dose-dependently at the range of 4~16 μM (Figure 5 and Figure 6). As previously reported, FPG can specifically digest oxidized purines, such as 8-oxoguanine, 5-hydroxycytosine, 5-hydroxyuracil, 2,6-diamino-4-hydroxy-5-N-methylformamidopyrimidine, and 4,6-diamino-5-formamidopyrimidine (35). However, endonuclease III can specifically digest oxidized pyrimidines, such as thymine glycol, 5,6-dihydrothymine, 5-hydroxydihydrothymine, 5-hydroxycytosine, 5-hydroxyuracil, and uracil glycol (39). This study showed for the first time that treatment with crocetin could reverse the formation of these As2O3-induced oxidative DNA adducts (Figure 5 and Figure 6) dose-dependently, although the detail mechanisms require further investigation. We did not however examine whether As2O3 can induce lipid peroxidation, and whether crocetin can reverse it. In 2017, Ma et al. found that As2O3 can increase lipid peroxidation in HUVEC cells (32), while the effects of crocetin on this requires further investigation. A scheme summarizing the effects of crocetin on the As2O3-induced NADPH oxidase activity, ROS levels and oxidative DNA adducts is shown in Figure 7.

Figure 7.
Figure 7.

The effects of As2O3 and crocetin on Endonuclease III-digestible adducts in HUVEC cells. Treatments of 4, 8 or 16 μM As2O3 with or without 10 or 20 μM crocetin for 12 h. Data are presented as mean±SD of at least three experiments. & and *statistically significant (p<0.05) compared with the untreated and control (As2O3 alone) groups, respectively.

In conclusion, crocetin is capable of reversing the As2O3-induced apoptosis, the activation of NADPH oxidase, and the production of ROS and oxidative DNA adducts in HUVEC cells. The antioxidant capacities of crocetin can aid cardiovascular disease prevention in clinical practice.

Acknowledgements

The experiments and the analysis of the results were partially assisted by Yun-Chi Wang and Yu-Chen Hsiau. This study was supported mainly by grants from Taichung Veterans General Hospital (TCVGH-VHCY1108603) and China Medical University Hospital and Asia University (CMU110-ASIA-01).

Footnotes

  • This article is freely accessible online.

  • Authors’ Contributions

    Tsai CL, Tsai CW and Chang WS conceived and designed the experiments. Tsai CW and Chang WS performed the experiments. Lin JC and He JL analyzed the data. Shih LC and He JL contributed reagents/materials/analysis tools. Tsai CW and Bau DT wrote and revised the article.

  • Conflicts of Interest

    The Authors declare no conflicts of interest in regard to this study.

  • Received August 19, 2021.
  • Revision received September 9, 2021.
  • Accepted September 10, 2021.

References

  1. ↵
    1. Rao Y,
    2. Li R and
    3. Zhang D
    : A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered. Sci China Life Sci 56(6): 495-502, 2013. PMID: 23645104. DOI: 10.1007/s11427-013-4487-z
    OpenUrlCrossRefPubMed
  2. ↵
    1. Yu X,
    2. Wang Z,
    3. Shu Z,
    4. Li Z,
    5. Ning Y,
    6. Yun K,
    7. Bai H,
    8. Liu R and
    9. Liu W
    : Effect and mechanism of Sorbus pohuashanensis (Hante) Hedl. flavonoids protect against arsenic trioxide-induced cardiotoxicity. Biomed Pharmacother 88: 1-10, 2017. PMID: 28092839. DOI: 10.1016/j.biopha.2016.12.130
    OpenUrlCrossRefPubMed
  3. ↵
    1. Raghu KG and
    2. Cherian OL
    : Characterization of cytotoxicity induced by arsenic trioxide (a potent anti-APL drug) in rat cardiac myocytes. J Trace Elem Med Biol 23(1): 61-68, 2009. PMID: 19203718. DOI: 10.1016/j.jtemb.2008.10.001
    OpenUrlCrossRefPubMed
  4. ↵
    1. Hsieh YC,
    2. Lien LM,
    3. Chung WT,
    4. Hsieh FI,
    5. Hsieh PF,
    6. Wu MM,
    7. Tseng HP,
    8. Chiou HY and
    9. Chen CJ
    : Significantly increased risk of carotid atherosclerosis with arsenic exposure and polymorphisms in arsenic metabolism genes. Environ Res 111(6): 804-810, 2011. PMID: 21605854. DOI: 10.1016/j.envres.2011.05.003
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bräuner EV,
    2. Nordsborg RB,
    3. Andersen ZJ,
    4. Tjønneland A,
    5. Loft S and
    6. Raaschou-Nielsen O
    : Long-term exposure to low-level arsenic in drinking water and diabetes incidence: a prospective study of the diet, cancer and health cohort. Environ Health Perspect 122(10): 1059-1065, 2014. PMID: 24927198. DOI: 10.1289/ehp.1408198
    OpenUrlCrossRefPubMed
  6. ↵
    1. Abhyankar LN,
    2. Jones MR,
    3. Guallar E and
    4. Navas-Acien A
    : Arsenic exposure and hypertension: a systematic review. Environ Health Perspect 120(4): 494-500, 2012. PMID: 22138666. DOI: 10.1289/ehp.1103988
    OpenUrlCrossRefPubMed
  7. ↵
    1. Chen Y,
    2. Wu F,
    3. Graziano JH,
    4. Parvez F,
    5. Liu M,
    6. Paul RR,
    7. Shaheen I,
    8. Sarwar G,
    9. Ahmed A,
    10. Islam T,
    11. Slavkovich V,
    12. Rundek T,
    13. Demmer RT,
    14. Desvarieux M and
    15. Ahsan H
    : Arsenic exposure from drinking water, arsenic methylation capacity, and carotid intima-media thickness in Bangladesh. Am J Epidemiol 178(3): 372-381, 2013. PMID: 23788675. DOI: 10.1093/aje/kwt001
    OpenUrlCrossRefPubMed
  8. ↵
    1. Moon KA,
    2. Guallar E,
    3. Umans JG,
    4. Devereux RB,
    5. Best LG,
    6. Francesconi KA,
    7. Goessler W,
    8. Pollak J,
    9. Silbergeld EK,
    10. Howard BV and
    11. Navas-Acien A
    : Association between exposure to low to moderate arsenic levels and incident cardiovascular disease. A prospective cohort study. Ann Intern Med 159(10): 649-659, 2013. PMID: 24061511. DOI: 10.7326/0003-4819-159-10-201311190-00719
    OpenUrlCrossRefPubMed
  9. ↵
    1. Tseng CH
    : Cardiovascular disease in arsenic-exposed subjects living in the arseniasis-hyperendemic areas in Taiwan. Atherosclerosis 199(1): 12-18, 2008. PMID: 18367191. DOI: 10.1016/j.atherosclerosis.2008.02.013
    OpenUrlCrossRefPubMed
  10. ↵
    1. Zimta AA,
    2. Schitcu V,
    3. Gurzau E,
    4. Stavaru C,
    5. Manda G,
    6. Szedlacsek S and
    7. Berindan-Neagoe I
    : Biological and molecular modifications induced by cadmium and arsenic during breast and prostate cancer development. Environ Res 178: 108700, 2019. PMID: 31520827. DOI: 10.1016/j.envres.2019.108700
    OpenUrlCrossRefPubMed
  11. ↵
    1. Wei S,
    2. Zhang H and
    3. Tao S
    : A review of arsenic exposure and lung cancer. Toxicol Res (Camb) 8(3): 319-327, 2019. PMID: 31160966. DOI: 10.1039/c8tx00298c
    OpenUrlCrossRefPubMed
  12. ↵
    1. Li H,
    2. Horke S and
    3. Förstermann U
    : Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis 237(1): 208-219, 2014. PMID: 25244505. DOI: 10.1016/j.atherosclerosis.2014.09.001
    OpenUrlCrossRefPubMed
  13. ↵
    1. Dwivedi N,
    2. Flora G,
    3. Kushwaha P and
    4. Flora SJ
    : Alpha-lipoic acid protects oxidative stress, changes in cholinergic system and tissue histopathology during co-exposure to arsenic-dichlorvos in rats. Environ Toxicol Pharmacol 37(1): 7-23, 2014. PMID: 24291368. DOI: 10.1016/j.etap.2013.10.010
    OpenUrlCrossRefPubMed
  14. ↵
    1. Nam KN,
    2. Park YM,
    3. Jung HJ,
    4. Lee JY,
    5. Min BD,
    6. Park SU,
    7. Jung WS,
    8. Cho KH,
    9. Park JH,
    10. Kang I,
    11. Hong JW and
    12. Lee EH
    : Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur J Pharmacol 648(1-3): 110-116, 2010. PMID: 20854811. DOI: 10.1016/j.ejphar.2010.09.003
    OpenUrlCrossRefPubMed
  15. ↵
    1. Zhang W,
    2. Li Y and
    3. Ge Z
    : Cardiaprotective effect of crocetin by attenuating apoptosis in isoproterenol induced myocardial infarction rat model. Biomed Pharmacother 93: 376-382, 2017. PMID: 28651239. DOI: 10.1016/j.biopha.2017.06.032
    OpenUrlCrossRefPubMed
  16. ↵
    1. Moradzadeh M,
    2. Sadeghnia HR,
    3. Tabarraei A and
    4. Sahebkar A
    : Anti-tumor effects of crocetin and related molecular targets. J Cell Physiol 233(3): 2170-2182, 2018. PMID: 28407293. DOI: 10.1002/jcp.25953
    OpenUrlCrossRefPubMed
  17. ↵
    1. Hosseinzadeh H,
    2. Sadeghnia HR,
    3. Ziaee T and
    4. Danaee A
    : Protective effect of aqueous saffron extract (Crocus sativus L.) and crocin, its active constituent, on renal ischemia-reperfusion-induced oxidative damage in rats. J Pharm Pharm Sci 8(3): 387-393, 2005. PMID: 16401388.
    OpenUrlPubMed
  18. ↵
    1. Shen XC and
    2. Qian ZY
    : Effects of crocetin on antioxidant enzymatic activities in cardiac hypertrophy induced by norepinephrine in rats. Pharmazie 61(4): 348-352, 2006. PMID: 16649553.
    OpenUrlPubMed
  19. ↵
    1. Diao SL,
    2. Sun JW,
    3. Ma BX,
    4. Li XM and
    5. Wang D
    : Influence of crocetin on high-cholesterol diet induced atherosclerosis in rats via anti-oxidant activity together with inhibition of inflammatory response and p38 MAPK signaling pathway. Saudi J Biol Sci 25(3): 493-499, 2018. PMID: 29692651. DOI: 10.1016/j.sjbs.2016.11.005
    OpenUrlCrossRefPubMed
  20. ↵
    1. Mancini A,
    2. Serrano-Díaz J,
    3. Nava E,
    4. D’Alessandro AM,
    5. Alonso GL,
    6. Carmona M and
    7. Llorens S
    : Crocetin, a carotenoid derived from saffron (Crocus sativus L.), improves acetylcholine-induced vascular relaxation in hypertension. J Vasc Res 51(5): 393-404, 2014. PMID: 25531977. DOI: 10.1159/000368930
    OpenUrlCrossRefPubMed
  21. ↵
    1. Cai J,
    2. Yi FF,
    3. Bian ZY,
    4. Shen DF,
    5. Yang L,
    6. Yan L,
    7. Tang QZ,
    8. Yang XC and
    9. Li H
    : Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway. J Cell Mol Med 13(5): 909-925, 2009. PMID: 19413885. DOI: 10.1111/j.1582-4934.2008.00620.x
    OpenUrlCrossRefPubMed
  22. ↵
    1. Shen XC and
    2. Qian ZY
    : Effect of crocetin on cardiac hypertrophy induced by overloading pressure in rats. Yao Xue Xue Bao 39(3): 172-175, 2004. PMID: 15171649.
    OpenUrlPubMed
  23. ↵
    1. Yang M,
    2. Mao G,
    3. Ouyang L,
    4. Shi C,
    5. Hu P and
    6. Huang S
    : Crocetin alleviates myocardial ischemia/reperfusion injury by regulating inflammation and the unfolded protein response. Mol Med Rep 21(2): 641-648, 2020. PMID: 31974615. DOI: 10.3892/mmr.2019.10891
    OpenUrlCrossRefPubMed
  24. ↵
    1. Lin CC,
    2. Chen KB,
    3. Tsai CH,
    4. Tsai FJ,
    5. Huang CY,
    6. Tang CH,
    7. Yang JS,
    8. Hsu YM,
    9. Peng SF and
    10. Chung JG
    : Casticin inhibits human prostate cancer DU 145 cell migration and invasion via Ras/Akt/NF-κB signaling pathways. J Food Biochem 43(7): e12902, 2019. PMID: 31353708. DOI: 10.1111/jfbc.12902
    OpenUrlCrossRefPubMed
  25. ↵
    1. Lee H,
    2. Wang S,
    3. Wu Y,
    4. Tsai C,
    5. Tsai F,
    6. Chung J,
    7. Huang C,
    8. Yang J,
    9. Hsu Y,
    10. Yin M,
    11. Li T and
    12. Tang C
    : Glucocerebroside reduces endothelial progenitor cell-induced angiogenesis. Food and Agricultural Immunology 30(1): 1033-1045, 2020. DOI: 10.1080/09540105.2019.1660623
    OpenUrlCrossRef
  26. ↵
    1. Huang TY,
    2. Peng SF,
    3. Huang YP,
    4. Tsai CH,
    5. Tsai FJ,
    6. Huang CY,
    7. Tang CH,
    8. Yang JS,
    9. Hsu YM,
    10. Yin MC,
    11. Huang WW and
    12. Chung JG
    : Combinational treatment of all-trans retinoic acid (ATRA) and bisdemethoxycurcumin (BDMC)-induced apoptosis in liver cancer Hep3B cells. J Food Biochem 44(2): e13122, 2020. PMID: 31837044. DOI: 10.1111/jfbc.13122
    OpenUrlCrossRefPubMed
  27. ↵
    1. Chang WS,
    2. Tsai CW,
    3. Yang JS,
    4. Hsu YM,
    5. Shih LC,
    6. Chiu HY,
    7. Bau DT and
    8. Tsai FJ
    : Resveratrol inhibited the metastatic behaviors of cisplatin-resistant human oral cancer cells via phosphorylation of ERK/p-38 and suppression of MMP-2/9. J Food Biochem 45(6): e13666, 2021. PMID: 34008860. DOI: 10.1111/jfbc.13666
    OpenUrlCrossRefPubMed
  28. ↵
    1. Tsai CL,
    2. Tsai CW,
    3. Chang WS,
    4. Lin JC,
    5. Hsia TC and
    6. Bau DT
    : Protective effects of baicalin on arsenic trioxide-induced oxidative damage and apoptosis in human umbilical vein endothelial cells. In Vivo 35(1): 155-162, 2021. PMID: 33402461. DOI: 10.21873/invivo.12243
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Liu S,
    2. Shen H,
    3. Xu M,
    4. Liu O,
    5. Zhao L,
    6. Liu S,
    7. Guo Z and
    8. Du J
    : FRP inhibits ox-LDL-induced endothelial cell apoptosis through an Akt-NF-{kappa}B-Bcl-2 pathway and inhibits endothelial cell apoptosis in an apoE-knockout mouse model. Am J Physiol Endocrinol Metab 299(3): E351-E363, 2010. PMID: 20530739. DOI: 10.1152/ajpendo.00005.2010
    OpenUrlCrossRefPubMed
  30. ↵
    1. Liu M,
    2. Xiang G,
    3. Lu J,
    4. Xiang L,
    5. Dong J and
    6. Mei W
    : TRAIL protects against endothelium injury in diabetes via Akt-eNOS signaling. Atherosclerosis 237(2): 718-724, 2014. PMID: 25463111. DOI: 10.1016/j.atherosclerosis.2014.10.013
    OpenUrlCrossRefPubMed
  31. ↵
    1. Yu CX,
    2. Zhang YY,
    3. Wu XY,
    4. Tang HX,
    5. Liang XQ,
    6. Xue ZM,
    7. Xue YD,
    8. Li J,
    9. Zhu H,
    10. Huo R and
    11. Ban T
    : Transient receptor potential melastatin 4 contributes to early-stage endothelial injury induced by arsenic trioxide. Toxicol Lett 312: 98-108, 2019. PMID: 31054354. DOI: 10.1016/j.toxlet.2019.04.035
    OpenUrlCrossRefPubMed
  32. ↵
    1. Ma Y,
    2. Ma Z,
    3. Yin S,
    4. Yan X and
    5. Wang J
    : Arsenic and fluoride induce apoptosis, inflammation and oxidative stress in cultured human umbilical vein endothelial cells. Chemosphere 167: 454-461, 2017. PMID: 27750169. DOI: 10.1016/j.chemosphere.2016.10.025
    OpenUrlCrossRefPubMed
  33. ↵
    1. Zhao Z,
    2. Li J,
    3. Zheng B,
    4. Liang Y,
    5. Shi J,
    6. Zhang J,
    7. Han X,
    8. Chu L,
    9. Chu X and
    10. Gao Y
    : Ameliorative effects and mechanism of crocetin in arsenic trioxide induced cardiotoxicity in rats. Mol Med Rep 22(6): 5271-5281, 2020. PMID: 33173984. DOI: 10.3892/mmr.2020.11587
    OpenUrlCrossRefPubMed
  34. ↵
    1. States JC,
    2. Srivastava S,
    3. Chen Y and
    4. Barchowsky A
    : Arsenic and cardiovascular disease. Toxicol Sci 107(2): 312-323, 2009. PMID: 19015167. DOI: 10.1093/toxsci/kfn236
    OpenUrlCrossRefPubMed
  35. ↵
    1. Tousoulis D,
    2. Briasoulis A,
    3. Papageorgiou N,
    4. Tsioufis C,
    5. Tsiamis E,
    6. Toutouzas K and
    7. Stefanadis C
    : Oxidative stress and endothelial function: therapeutic interventions. Recent Pat Cardiovasc Drug Discov 6(2): 103-114, 2011. PMID: 21513492. DOI: 10.2174/157489011795933819
    OpenUrlCrossRefPubMed
  36. ↵
    1. Wang C,
    2. Ning Z,
    3. Wan F,
    4. Huang R,
    5. Chao L,
    6. Kang Z,
    7. Yang F,
    8. Zhong G,
    9. Li Y,
    10. Pan J,
    11. Tang Z and
    12. Hu L
    : Characterization of the cellular effects and mechanism of arsenic trioxide-induced hepatotoxicity in broiler chickens. Toxicol In Vitro 61: 104629, 2019. PMID: 31442540. DOI: 10.1016/j.tiv.2019.104629
    OpenUrlCrossRefPubMed
  37. ↵
    1. Zhong G,
    2. Wan F,
    3. Ning Z,
    4. Wu S,
    5. Jiang X,
    6. Tang Z,
    7. Huang R and
    8. Hu L
    : The protective role of autophagy against arsenic trioxide-induced cytotoxicity and ROS-dependent pyroptosis in NCTC-1469 cells. J Inorg Biochem 217: 111396, 2021. PMID: 33610032. DOI: 10.1016/j.jinorgbio.2021.111396
    OpenUrlCrossRefPubMed
  38. ↵
    1. Meng XM,
    2. Ren GL,
    3. Gao L,
    4. Yang Q,
    5. Li HD,
    6. Wu WF,
    7. Huang C,
    8. Zhang L,
    9. Lv XW and
    10. Li J
    : NADPH oxidase 4 promotes cisplatin-induced acute kidney injury via ROS-mediated programmed cell death and inflammation. Lab Invest 98(1): 63-78, 2018. PMID: 29106395. DOI: 10.1038/labinvest.2017.120
    OpenUrlCrossRefPubMed
  39. ↵
    1. Nickoloff JA,
    2. Spirio LN and
    3. Reynolds RJ
    : A comparison of calcium phosphate coprecipitation and electroporation. Implications for studies on the genetic effects of DNA damage. Mol Biotechnol 10(2): 93-101, 1998. PMID: 9819809. DOI: 10.1007/BF02760857
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Protective Effects of Crocetin on Arsenic Trioxide-induced Oxidative Stress in Human Umbilical Vein Endothelial Cells
CHUNG-LIN TSAI, CHIA-WEN TSAI, WEN-SHIN CHANG, JIUNN-CHERNG LIN, LIANG-CHUN SHIH, JIE-LONG HE, DA-TIAN BAU
In Vivo Nov 2021, 35 (6) 3157-3163; DOI: 10.21873/invivo.12610
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords